CN112424233A - 包含颗粒蛋白前体的融合蛋白 - Google Patents

包含颗粒蛋白前体的融合蛋白 Download PDF

Info

Publication number
CN112424233A
CN112424233A CN201980039158.0A CN201980039158A CN112424233A CN 112424233 A CN112424233 A CN 112424233A CN 201980039158 A CN201980039158 A CN 201980039158A CN 112424233 A CN112424233 A CN 112424233A
Authority
CN
China
Prior art keywords
polypeptide
protein
seq
sequence
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980039158.0A
Other languages
English (en)
Chinese (zh)
Inventor
吉尔伯特·迪保罗
托德·P·洛根
凯瑟琳·M·梦露
安基塔·斯利瓦斯塔瓦
贝蒂娜·范伦格里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CN112424233A publication Critical patent/CN112424233A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980039158.0A 2018-06-18 2019-06-18 包含颗粒蛋白前体的融合蛋白 Pending CN112424233A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862686579P 2018-06-18 2018-06-18
US62/686,579 2018-06-18
US201862746338P 2018-10-16 2018-10-16
US62/746,338 2018-10-16
PCT/US2019/037695 WO2019246071A1 (en) 2018-06-18 2019-06-18 Fusion proteins comprising progranulin

Publications (1)

Publication Number Publication Date
CN112424233A true CN112424233A (zh) 2021-02-26

Family

ID=67138158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980039158.0A Pending CN112424233A (zh) 2018-06-18 2019-06-18 包含颗粒蛋白前体的融合蛋白

Country Status (17)

Country Link
US (3) US20210284702A1 (cg-RX-API-DMAC7.html)
EP (1) EP3807322A1 (cg-RX-API-DMAC7.html)
JP (1) JP7517997B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210027377A (cg-RX-API-DMAC7.html)
CN (1) CN112424233A (cg-RX-API-DMAC7.html)
AU (1) AU2019288212B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020025306A2 (cg-RX-API-DMAC7.html)
CA (1) CA3101202A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003255A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20081591A (cg-RX-API-DMAC7.html)
IL (1) IL279510B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020012518A (cg-RX-API-DMAC7.html)
PE (1) PE20210323A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552189A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202011743SA (cg-RX-API-DMAC7.html)
TW (1) TWI874321B (cg-RX-API-DMAC7.html)
WO (1) WO2019246071A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
AU2016270587B2 (en) * 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
US20210396772A1 (en) * 2018-10-16 2021-12-23 Denali Therapeutics Inc. Methods for treating and monitoring progranulin-associated disorders
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) * 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CN116133684B (zh) * 2020-05-27 2025-07-18 阿里亚利斯治疗公司 抗人nr1抗体衍生物
US20210393787A1 (en) * 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
KR102666958B1 (ko) * 2020-09-18 2024-05-23 한양대학교 산학협력단 PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물
EP4215607A4 (en) * 2020-09-18 2024-11-06 IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) Ptpsigma-fc fusion protein and pharmaceutical composition comprising same
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
EP4229419A2 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
AR128003A1 (es) * 2021-12-17 2024-03-20 Denali Therapeutics Inc PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS
WO2023198661A1 (en) * 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
CN119213030A (zh) * 2022-05-16 2024-12-27 戴纳立制药公司 转铁蛋白受体结合结构域和包含其的蛋白
JP2024037109A (ja) * 2022-09-06 2024-03-18 国立大学法人九州大学 分析容器、前処理方法、代謝物解析方法、タンパク質解析方法、及び質量分析方法
EP4630030A2 (en) * 2022-12-06 2025-10-15 ProteinQure Inc. Targeting sortilin
EP4731669A2 (en) * 2023-06-21 2026-04-29 Eli Lilly and Company Compounds for the delivery of granulin across the blood brain barrier
WO2025051953A1 (en) * 2023-09-07 2025-03-13 Novo Nordisk A/S Sortilin-1 binders, constructs and uses thereof
TW202542190A (zh) 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法
WO2025166077A1 (en) * 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
EP4755905A1 (en) 2024-12-05 2026-06-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Truncated progranulin protein and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
WO2016207240A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
US20170210808A1 (en) * 2015-04-07 2017-07-27 Alector Llc Anti-sortilin antibodies and methods of use thereof
CN107698684A (zh) * 2016-08-03 2018-02-16 广东东阳光药业有限公司 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
US20170210808A1 (en) * 2015-04-07 2017-07-27 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2016207240A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
CN107698684A (zh) * 2016-08-03 2018-02-16 广东东阳光药业有限公司 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白

Also Published As

Publication number Publication date
WO2019246071A1 (en) 2019-12-26
PE20210323A1 (es) 2021-02-18
EP3807322A1 (en) 2021-04-21
BR112020025306A2 (pt) 2021-03-09
JP2021527656A (ja) 2021-10-14
CA3101202A1 (en) 2019-12-26
IL279510A (en) 2021-01-31
PH12020552189A1 (en) 2021-06-28
US20210284702A1 (en) 2021-09-16
AU2019288212B2 (en) 2026-04-16
ECSP20081591A (es) 2021-01-29
US20260001925A1 (en) 2026-01-01
AU2019288212A1 (en) 2020-12-03
TWI874321B (zh) 2025-03-01
KR20210027377A (ko) 2021-03-10
CL2020003255A1 (es) 2021-05-28
IL279510B2 (en) 2025-11-01
JP7517997B2 (ja) 2024-07-17
TW202016152A (zh) 2020-05-01
US20230406898A1 (en) 2023-12-21
IL279510B1 (en) 2025-07-01
SG11202011743SA (en) 2021-01-28
MX2020012518A (es) 2021-02-16

Similar Documents

Publication Publication Date Title
US20260001925A1 (en) Fusion proteins comprising progranulin
US20230265137A1 (en) Progranulin variants
JP7854267B2 (ja) 酵素補充療法用酵素を含む融合タンパク質
JP2020508049A (ja) 操作されたトランスフェリン受容体結合ポリペプチド
JP2020530293A (ja) 操作されたトランスフェリン受容体結合ポリペプチド
JP2020508053A (ja) 操作されたポリペプチド
HK40046687A (en) Fusion proteins comprising progranulin
EA049541B1 (ru) Слитые белки, содержащие програнулин
EA049817B1 (ru) Варианты програнулина
HK40079659A (en) Progranulin variants
HK40063309A (en) Fusion proteins comprising enzyme replacement therapy enzymes
HK40031685A (en) Fusion proteins comprising enzyme replacement therapy enzymes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046687

Country of ref document: HK